ArriVent BioPharma is rated a Strong Buy, driven by Firmonertinib’s clinical progress and de-risking. Click here to read my ...
British trade department minister Chris Bryant said the government had been hacked in October, partly confirming a report in ...
Gossamer Bio advances the Feb. 2026 PROSERA Phase 3 readout for seralutinib in PAH, with expanded endpoints and a new ILD trial. Learn why GOSS stock is a hold.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback